Bristol Myers Squibb Reports Preliminary Phase 3 KarXT Data in Alzheimer's Psychosis
Bristol Myers Squibb on Wednesday released preliminary Phase 3 results from two studies in its ADEPT program testing KarXT in psychosis associated with Alzheimer's disease. According to the company, both short- and long-term treatment with the drug reduced hallucinations and delusions in patients.
The readout is the first clinical data presented from the ADEPT program, which evaluates KarXT — the company's schizophrenia drug — in patients experiencing Alzheimer's-related psychosis. The company described the findings as preliminary.
The initial announcements did not include detailed efficacy statistics from the two trials. Bristol Myers Squibb reported revenue of 48.20 billion USD in fiscal 2025.
Important questions to consider
The company said short- and long-term KarXT treatment reduced symptoms in patients with psychosis associated with Alzheimer's disease, including hallucinations and delusions. The results are preliminary.
KarXT is Bristol Myers Squibb's schizophrenia drug. The ADEPT program consists of two Phase 3 studies evaluating the drug for psychosis associated with Alzheimer's disease.
Yes. The company said it was presenting the first clinical data from the two Phase 3 studies in the ADEPT program.
Sources
- Bristol Myers Squibb Says KarXT Reduces Hallucinations and Delusions In Preliminary Alzheimer's Trials
Benzinga
- Bristol's schizophrenia drug helps Alzheimer's-related psychosis symptoms, preliminary data shows
Reuters
- Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer's Disease
Business WirePress release